4.7 Article

The mechanism of action of glatiramer acetate treatment in multiple sclerosis

期刊

NEUROLOGY
卷 74, 期 1, 页码 S25-S30

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e3181c97e39

关键词

-

资金

  1. Teva Neuroscience
  2. National Institutes of Health [RO1 NS 37513]
  3. National Multiple Sclerosis Society
  4. NIH/NIAID

向作者/读者索取更多资源

Objective: Glatiramer acetate (formerly known as copolymer 1) is the major noninterferon immunomodulatory agent used in the treatment of relapsing-remitting multiple sclerosis. Its mechanism of action over the past 40 years has evolved with our understanding of the immune response. Methods: We review the various mechanisms that have been proposed for this random polymer over the years, with emphasis on recent methods that utilize modern immunologic techniques. Results: Studies describing processes such as immune deviation and effects on regulatory T cells and antigen-presenting cells are presented. Conclusions: Effects of glatiramer acetate on the immune response have evolved as our technical abilities and knowledge of the immune response itself have developed. NEUROLOGY 2010; 74(Suppl 1):S25-S30

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据